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We read with much interest and appreciation the research
article by Nuttall and collaborators on the complications
of immunization with bacillus Calmette–Gue´rin (BCG) in
children treated with highly-active antiretroviral therapy
(HAART) in South Africa.1 Brieﬂy stated, Nuttall and collabora-
tors reported a rate of 6% (21/352) for BCG adverse reactions in
HIV-infected children treated with HAART. This rate is
comparable to the rates of 2.7% reported by Puthanakit et al.
in Thailand2 and 4.5% reported by us in Brazil.3 Overall, these
rates contrast with estimates from earlier studies conducted in
Africa.4,5
In agreement with the study by Nuttall and collaborators, we
noted adverse reactions to be prevalent in female children (3/3)
and the events occurred during the ﬁrst six months of life. The
viral load in these children ranged from 750,000 to 5,130,000
copies/ml. However, unlike their study, ours corroborated the
notion that a low CD4+ T-lymphocyte cell count is an
independent risk factor for adverse reactions to BCG (27.2%
CD4+ T-lymphocytes in one child despite the child having had
esophagitis caused by cytomegalovirus). In our series, there
were two cases in which a temporal relationship was found
between the drop in viral load after HAART, an increase in CD4+
T-lymphocyte percentage, and the development of the compli-
cations clearly related to immune reconstitution inﬂammatory
syndrome (IRIS). The clinical ﬁndings were indicative of
localized axillary adenopathy ipsilateral to the BCG vaccination,
one being suppurative. In agreement with the recommendations
of the Brazilian Ministry of Health6 and the study by Alexander
and Rode,7 we contraindicated handling of the lesions, which
can worsen due to a secondary bacterial infection. The children
received treatment with isoniazid for six months, following
the recommendations of the Ministry of Health,6 also as referred
to by Puthanakit et al.8 These studies demonstrated that there
is a relationship between predominantly localized adverse
reactions to the BCG vaccine in HIV-infected children and IRIS.
These ﬁndings reinforce the need to re-evaluate the recom-
mendations of the World Health Organization that children who
are known to be HIV-infected, even if asymptomatic, should no
longer be immunized with the BCG vaccine.9 Although delaying
BCG immunization eliminates the risk of BCG disease, full
contraindication of the vaccination will increase the occurrence
of the lethal forms of tuberculosis in HIV-exposed/uninfected
children, given the difﬁculties in warranting late vaccination.10
BCG vaccinated HIV-exposed children, therefore, require judi-
cious care during the ﬁst six months after the initiation of
HAART.
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